Post by icemandios on Sept 9, 2020 12:56:59 GMT
Phio Pharmaceuticals to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL™) therapeutic platform. The Company's efforts are focused on silencing tumor-induced suppression of the immune system through its proprietary INTASYL platform with utility in immune cells and the tumor micro-environment. Our goal is to develop powerful INTASYL therapeutic compounds that can weaponize immune effector cells to overcome tumor immune escape, thereby providing patients a powerful new treatment option that goes beyond current treatment modalities. For additional information, visit the Company's website, www.phiopharma.com.
MARLBOROUGH, Mass., Sept. 9, 2020 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that its chief executive officer, Dr. Gerrit Dispersyn, will present at the upcoming H.C. Wainwright 22nd Annual Global Investment Conference, held virtually this year from September 14 – 16, 2020.
Dr. Dispersyn is scheduled to present on Wednesday, September 16th, at 11:30 a.m. ET. Interested parties may access a live webcast of the presentation at wsw.com/webcast/hcw7/phio/1608336.
An archived version of the webcast and the slides used in the presentation will be made available on the "Investors – Events and Presentations" section of the Company's website after the live event.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL™) therapeutic platform. The Company's efforts are focused on silencing tumor-induced suppression of the immune system through its proprietary INTASYL platform with utility in immune cells and the tumor micro-environment. Our goal is to develop powerful INTASYL therapeutic compounds that can weaponize immune effector cells to overcome tumor immune escape, thereby providing patients a powerful new treatment option that goes beyond current treatment modalities. For additional information, visit the Company's website, www.phiopharma.com.